Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Allogeneic Transplantation for Refractory Hodgkin Lymphoma
NCT00908180Phase 2Unknown
- Sponsor
- Cancer Research UK
- Start
- Jul 2009
- Primary completion
- Jul 2014
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of alemtuzumab in Hodgkin lymphoma (HL), sponsored by Cancer Research UK. Status: unknown.
02
Drugs
alemtuzumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00908180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00908180.